Disulfiram tablets, disulfiram tablets india, disulfiram tablets manufacturers india
Disulfiram tablets, Disulfiram tablets India, Disulfiram tablets manufacturers India, side effects Disulfiram tablets manufacturers, Taj Pharma India, Disulfiram tablets overdose, Disulfiram tablets drug, Disulfiram tablets composition, Manufacturing Pharmaceutical, Disulfiram tablets brand, contains, Disulfiram tablets India, Disulfiram tablets side
effects, Disulfiram tablets use, Disulfiram tablets overdose, Disulfiram tablets drug, Disulfiram tablets composition, Disulfiram tablets Manufacturing, Pharmaceutical manufacturers, Disulfiram tablets contains, Disulfiram tablets Manufacturing, Disulfiram tablets Pharmaceutical manufacturers, Disulfiram tablets side effects, Disulfiram tablets use
Disulfiram tablets ,Disulfiram tablets overdose, Disulfiram tablets drug Disulfiram tablets, composition Disulfiram tablets, Pharmaceuticals, Allopathic Products, Manufacturer exporter, Supplier Disulfiram tablets India formulations , manufacturers Taj Products Pharmaceuticals Products, Manufacturer exporter, Supplier india formulations, Disulfiram
tablets tablets, medicines injections, (Disulfiram tablets) Tablets, Pharmaceutical Product, Disulfiram tablets tablets, Manufacturing pharmaceuticals manufacturing pharma Disulfiram tablets tablets pharmacy Tablets pharmaceutical drugs, pharmaceutical, formulations Disulfiram tablets tablets, active pharmaceutical ingredients, manufacturer
pharmaceutical, packaging Disulfiram tablets tablets, pharmaceutical drugs, global pharmaceutical Disulfiram tablets tablets, capsules, pharmaceutical raw materials, pharmaceutical drug, Pharmaceuticals manufacturer, Pharmacological Products Disulfiram tablets, tablets Tablets, Exporter India, Capsules Injections, manufacturing
Pharmaceuticals, Manufacturer India, Tablets Disulfiram tablets, Tablets manufacturers Disulfiram tablets, Tablets Manufacturing, Disulfiram tablets tablets, Pharmaceutical manufacturers Taj Pharma India
Disulfiram tablets Each tablet contains:
The excipients include: povidon, carmelose-sodium,
magnesium stearate and microcrystal cellulose. Drug Uses :
This medication is used to help treat alcoholism. This drug is not a cure for alcoholism and must be used in combination with supportive
therapy and counseling. This medication must never be used without a person's knowledge. How to use :
Take this medication by mouth, usually one or two tablets daily as directed by your doctor. Tablets can be crushed or mixed with liquid if
swallowing is a problem. Do not take this medication for at least 12 hours after drinking alcohol.
While taking this medication, it is extremely important you avoid alcohol in all forms including beer, wine, aftershave lotions, mouthwash,
colognes, liquid medications. Read labels carefully, including those of nonprescription products, and ask your pharmacist about the
alcohol content if you are uncertain. Drug Class and Mechanism :
Disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even
small amounts of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage. During alcohol metabolism after
Disulfiram intake, the concentration of acetaldehyde occurring in the blood may be 5 to 10 times higher than that found during metabolism
of the same amount of alcohol alone. Accumulation of acetaldehyde in the blood produces a complex of highly unpleasant symptoms
referred to as the Disulfiram-alcohol reaction. This reaction, which is proportional to the dosage of both Disulfiram and alcohol, will persist
as long as alcohol is being metabolized. Disulfiram does not appear to influence the rate of alcohol elimination from the body. Missed Dose :
If you miss a dose of Sumycin , take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your
regular dosing schedule. Do not take 2 doses at once.
For Information about Generic Medicines : firstname.lastname@example.org Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.
Information for Health Care Professionals
*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited). TAJ GROUP PHARMACEUTICAL B U S I N E S S TAJ GROUP PHARMACEUTICAL B U S I N E S S
Note: This site contains medical information that is intended for
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this Report is not intended to give investment
doctors or medical practitioner only and is not meant to substitute for
advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions
the advice provided by a medical professional. Always consult a
regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider. Active
physician if you have health concerns. Use and access of this site is
P h a r m a c e u t i c a l I n g r e d i e n t s m a n u f a c t u r e r , e x p o r t e r , d r u g i n g r e d i e n t s , p h a r m a c e u t i c a l s , I n d i a
Additionally, contact information on this Report cannot be used to report adverse drug events. If you are a physician, please follow the procedures
required by your country's regulations. Please choose one of the given options to contact us and we will respond to
Copyright 2012 Taj Pharma Group (India),. All rights reserved. DISLAIMER THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION. NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.
This document includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as” anticipate”, “target”, “expect”, “estimate”, “intend”, “expected”, “plan”, “goal” believe”, or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.
Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional.
This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional.
According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries. www.tajpharma.com
The company medicines are present in France, Georgia, Egypt and CIF countries. Taj Pharmaceuticals Limited Working For Healthier World
Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.
The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements. TAJ GROUP PHARMACEUTICAL B U S I N E S S
Further Details Please Visit: www.tajpharma.com
The contents and design of this website, including Authority logos, are the property of the Taj Pharmaceuticals Limited India, and are protected under copyright law and international treaty.
All rights reserved. Except under the conditions described in the Copyright Act 1968 and subsequent amendments, no part of this website may be reproduced or communicated by any process without prior permission in writing from
Copyright 2004-2011 Taj Pharmaceuticals Limited. All rights reserved. Legal NoticeThe products discussed herein may have different product labeling in different countries. The product informationprovided in this site is intended only for the residents of India. TAJ GROUP PHARMACEUTICAL B U S I N E S S
Single-pass CO2-laser skin resurfacing in combination with cold air cooling. Efficacy and patient satisfaction of a prospective side-by- side study Christian Raulin, Hortensia Grema, Laserklinik Karlsruhe, Karlsruhe, Germany Word count: 1998 Correspondence address: Christian Raulin, M.D. Laserklinik Karlsruhe Kaiserstr. 104 Germany 76133 Karlsruhe www: Abstract: Ablative
Information for Patients with a Bladder Substitution Dr Celi Varol MB BS FRACS (Urology) Elizabeth Marshall Dip Health Sc (Nursing) Following the operation you will have to change your daily routine. Although this may be difficult at the start, with time you will learn to integrate these changes into your daily life. This information brochure has been developed to ass